Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Alexion has agreed to pay $30 million upfront and as much as $730 million in milestones for global rights to NI006, a preclinical-to-Phase 1b antibody from…
In rare disease, Alexion completed the in-licensing of NI006, a Phase 1 monoclonal antibody from Neurimmune for transthyretin amyloid cardiomyopathy, and…
Neurimmune expanded its AstraZeneca/Alexion collaboration to NI009, a preclinical monoclonal antibody targeting lambda light-chain fibrils in AL amyloidosis:…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Alexion (AstraZeneca Rare Disease) closed an exclusive global collaboration and license agreement with Switzerland's Neurimmune in March 2022 for NI006 — now the human monoclonal antibody cliramitug (development code ALXN2220) — a first-in-class amyloid depleter for transthyretin amyloid cardiomyopathy (ATTR-CM). Neurimmune received $30M upfront with up to $730M in development, regulatory and commercial milestones plus tiered low-to-mid teen royalties ($760M total potential), and retained the ongoing Phase 1b study before Alexion took over development. The depleter mechanism aimed to clear existing cardiac amyloid, differentiating it from Pfizer's tafamidis stabilizer and the RNA silencers from Alnylam/BridgeBio. The thesis has since been de-risked: Phase 1 results (NI006-101, NCT04360434) published in NEJM in May 2023 showed substantial cardiac ATTR depletion with no drug-related serious adverse events, and Alexion advanced the asset into the registrational Phase 3 DepleTTR-CM trial (NCT06183931; initiated January 2024, ~1,181 patients, primary completion estimated 2027), now active and no longer recruiting. In December 2025 the companies expanded the partnership to a second fibril depleter, NI009 for AL amyloidosis (a separate agreement worth up to $780M in milestones plus royalties).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Neurimmune AG (NI006 license) (this deal) | 2022 | $760M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2022 deals · AstraZeneca PLC deals · Cardiovascular deals